Polymyalgia Rheumatica Not Linked to Increased Mortality
In a long-term follow-up study, patients with isolated polymyalgia rheumatica (PMR) and biopsy-confirmed giant cell arteritis (GCA) had no increased all-cause mortality compared with matched individuals; men with PMR showed lower mortality.
METHODOLOGY:
Researchers assessed long-term all-cause mortality in patients with PMR using data from a prospective, population-based inception cohort in Norway between 1987 and 1997 that was followed for 38 years.
They included 274 patients with isolated PMR (mean age at diagnosis, 71.9 years; 66.1% women) and 63 patients with GCA (mean age at diagnosis, 71.6 years; 76.2% women), of whom 22 had coexisting PMR and GCA.
PMR was defined with the fulfilment of criteria suggested by Bird and colleagues, and the diagnosis of GCA was confirmed with a positive temporal artery biopsy.
Each case of PMR and GCA was matched with 15 individuals from the population registry on the basis of sex, age at inclusion, and residency, resulting in a total of 4110 and 945 individuals, respectively.
Mortality and survival were assessed using the standard mortality ratio (SMR), with patients being followed up till death or until December 2024.
TAKEAWAY:
Among all patients with PMR, 96% had died by the end of the study, with a mean follow-up duration of 14 years and a maximum of 35.3 years.
All-cause mortality in patients with PMR or GCA did not differ significantly from that in matched individuals.
Men with PMR had significantly lower all-cause mortality (SMR, 0.77; 95% CI, 0.62-0.95); no significant sex-related differences were observed in patients with GCA.
The overall cumulative survival in patients with PMR or GCA was not significantly different from that in the matched individuals.
IN PRACTICE:
"Our findings align with previous evidence reinforcing that isolated PMR does not significantly impact survival negatively, offering reassurance to both patients and clinicians regarding its long-term prognosis," the authors wrote.
SOURCE:
This study was led by Stig Tengesdal, Sørlandet Hospital, Kristiansand, Norway. It was published online on July 21, 2025, in Arthritis Research & Therapy.
LIMITATIONS:
The Bird's criteria may have relatively poor specificity for PMR. The prevalence of large vessel vasculitis may have been underestimated in the PMR cohort. Cases of malignancy could not be identified and excluded as data from medical charts were limited.
DISCLOSURES:
This study did not receive any specific funding. The authors declared having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nearby super-Earth K2-18 b may be a water-rich ocean planet: 'This has certainly increased the chances of habitability'
When you buy through links on our articles, Future and its syndication partners may earn a commission. The saga surrounding Neptune-size "super-Earth" exoplanet K2-18 b just got a whole lot more interesting. For a quick recap, this is the world a team of scientists recently suggested could host life — to the dismay of other scientists in the community, who felt the announcement failed to include necessary caution. While signs of life on the world have failed to conclusively present themselves to the James Webb Space Telescope (JWST), the powerful space telescope has discovered that this planet is so rich in liquid water that it could be an ocean, or "Hycean" world. "This has certainly increased the chances of habitability on K2-18 b" Nikku Madhusudhan, the University of Cambridge scientist behind the original K2-18b discovery as well as the new study, told "This is a very important development and further increases the chance of a Hycean environment in K2-18 b. It confirms K2-18 b to be our best chance to study a potential habitable environment beyond the solar system at the present time." The story regarding the habitability of K2-18 b began back in April 2025, when Madhusudhan and fellow researchers from the University of Cambridge announced they had found what they called the "strongest evidence yet" of life beyond the solar system around this distant super-Earth (it's around nine times as massive as our planet). The evidence came from the tentative detection of molecules that, when found in the atmosphere of Earth, are typically the result of biological processes of living things. The pressure was then on to confirm these potential biosignatures: dimethyl sulfide and dimethyl disulfide. The team set about this by observing four separate instances of K2-18 b crossing, or "transiting," the face of its parent red dwarf star, located about 124 light-years away, during its roughly 33-Earth-day orbit. Because chemicals absorb and emit light at characteristic wavelengths, when light from a parent star passes through a planet's atmosphere, the molecules in that atmosphere leave their telltale fingerprints in the spectrum of starlight. "With four additional transit observations using JWST, we have measured the spectrum of K2-18 b's atmosphere with unprecedented precision," Renyu Hu, the new study's team leader and a NASA Jet Propulsion Lab scientist, told "The spectrum allowed us to conclusively detect both methane and carbon dioxide in the planet's atmosphere and to constrain their abundances. This information points to a planet with a water-rich interior." Hu explained that the team searched for signals of dimethyl sulfide and other organic sulfur molecules in the spectrum using several independent models, but did not find conclusive evidence for their presence. "This was not necessarily disappointing," Hu continued. "We're excited about establishing the planet's water-rich nature." Is K2-18 b a ocean world? Saying it's now confirmed that K2-18 b is water-rich, Hu explained that the next step is to discover if the planet possesses a global liquid water ocean. Ironically, one of the most positive signs of such an ocean is the fact that the atmosphere of this super-Earth appears to lack water vapor. "The spectrum we obtained does not show signs of water vapor. If the atmosphere truly lacks water, this suggests that water has been depleted — most likely through condensation," Hu said. "On Earth, this process is known as the 'cold trap,' and geoscientists consider it essential for retaining water over billions of years by preventing it from escaping to space. "Observing a similar process on an exoplanet would be very exciting. Rigorously confirming the absence of water can by itself be a scientifically important goal for future observations," Hu said. However, Hu cautioned that the spectrum detected by the JWST could also be explained by an alternative model in which the atmosphere actually contains abundant water vapor. Establishing whether K2-18 b and other similar temperate, sub-Neptune-sized planets possess liquid water oceans, Hu says, will also require detecting the presence of a broader set of atmospheric gases beyond methane and carbon dioxide. It would also require an absence of molecules like ammonia, carbon monoxide and sulfur dioxide, which, as of yet, have indeed not been detected in the atmosphere of K2-18 b "This conclusion is based on theoretical work by my group and several others," Hu added. "With the new observations providing valuable context, we've summarized these insights into a roadmap to help guide future observations and studies." Meanwhile, the search for the biosignatures, dimethyl sulfide and dimethyl disulfide, is far from done; while not hitting the significance level required for a confirmation, this research did provide a stronger signal from these molecules than were provided by previous examinations. "The evidence for dimethyl sulfide in the present work is significantly higher than what we had with our previous observations in the same near-infrared wavelength range," Madhusudhan said. "However, this evidence is still not high enough to claim a conclusive detection. "We also need to be able to distinguish dimethyl sulfide from other possible contributors, such as methyl mercaptan, which is also a biosignature on Earth." Related Stories: — The mystery of how strange cosmic objects called 'JuMBOs' went rogue — These mysterious objects born in violent clashes between young star systems aren't stars or planets — James Webb Space Telescope dives into the atmosphere of a mystery rogue planet or failed star It looks certain that K2-18 b will continue to hold the interest of astronomers for some time. "It is great that we are able to infer tentative signs of potential biosignatures with current JWST observations, but significantly more time is needed for conclusive detections. A key question is whether the atmosphere contains one or more biosignatures," Madhusudhan said. "At the same time, extensive theoretical and experimental efforts are needed to robustly identify biological and non-biological pathways for candidate biosignature molecules." One thing the team is sure of, though, is the progress made thus far in the study of K2-18 b wouldn't have been possible without the JWST. And, the $10 billion space telescope is set to play a key role in the future investigation of this super-Earth. "Our observations and analyses add to the growing list of exciting discoveries that highlight the truly transformative science enabled by JWST," Hu concluded. "While we found its Near-Infrared Spectrograph [NIRSpec] particularly well suited to address the goals of our study, other JWST instruments or observational modes could provide complementary and highly valuable information to further enhance our understanding of this planet." The team's research is available as a preprint on the paper repository arXiv. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Netflix's ‘3 Body Problem' Adds ‘Game of Thrones' Alum to Season 2 Cast (Exclusive)
Netflix's sci-fi epic 3 Body Problem is adding another familiar face from Game of Thrones. The production — which is from Thrones creators David Benioff and D.B. Weiss along with Alexander Woo — has cast Alfie Allen in a recurring role in season two. In addition, David Yip (The Chinese Detective) and Jordan Sunshine (Wonder Pets) have also joined the cast. They join previously announced new cast members Claudia Doumit and Ellie De Lange. More from The Hollywood Reporter This Tennessee Grandma Just Might Be the Savior of Sitcoms 'Long Story Short' From 'BoJack Horseman' Creator Lands Season 2 Renewal Ahead of Series Premiere Netflix Reveals 10-Title Colombia Slate Featuring True Crime, Franchise Finales and Political Drama The season has just started production in Budapest, Hungary. The production has also revealed who from the first season's cast is making the vast time jump into the season two storyline: Jess Hong as Jin, Benedict Wong as Da Shi, Eiza González as Auggie, Jovan Adepo as Saul, Saamer Usmani as Raj, Liam Cunningham as Wade, Marlo Kelly as Tatiana, Sea Shimooka as Sophon and Josh Brener as Kent. In addition, Emmy-winning Thrones director Miguel Sapochnik ('Battle of the Bastards') is reuniting with Benioff and Weiss to executive produce and direct multiple episodes along with fellow Thrones alum Jeremy Podeswa, who also worked on season one. The season two description is brief and cryptic: 'As the alien invasion nears, humanity prepares — on Earth and elsewhere.' Since his breakout role as Theon Greyjoy on Thrones, Allen has appeared in John Wick, Jojo Rabbit and most recently starred in the Dutch crime drama Safe Harbor. In addition to Cunningham (who played Davos Seaworth on Thrones), the show's first season also featured Thrones alum John Bradley and Jonathan Pryce, along with cameo appearance by Conleth Hill. 3 Body Problem is an adaptation of author Cixin Liu's trilogy that tells the story of an alien invasion set over a vast period of time. The first season debuted last year to critical acclaim and topped Netflix's TV chart for several weeks. The streamer has renewed the show for a second and third season to conclude the story. 'We're thrilled that we get to tell this story through to its epic conclusion,' the showrunners said in a statement at the time. 'Ever since we read the last page of Cixin Liu's magnificent trilogy, we hoped we'd be able to bring the audience to the end of the universe with us. Here we go!' In addition, Benioff and Weiss renewed their overall deal with the streamer to write, produce and direct new series and films. In addition to the continuation of 3 Body Problem, they are currently working on the recently announced series Death by Lightning. Woo also has an overall deal at the streamer. Benioff previously told The Hollywood Reporter for a cover story that the second season of 3 Body Problem would be even better than the first: 'Liu Cixin's created this indelible trilogy and the books just get better for me. The second book is far better than the first, and the third book just completely blew my mind. The story just gets more and more ambitious as it goes, and it takes a huge leap in book two. So I feel like if we survive to the second season, we're going to be in a good place.' The series is also executive produced by Bernadette Caulfield, Duncan Muggoch, Rian Johnson, Ram Bergman, Nena Rodrigue, Qi Lin, Jilong Zhao, Brad Pitt, Jeremy Kleiner, Dede Gardner, Rosamund Pike, and Robie Uniacke. While there's no premiere date yet for season two, a return in 2026 seems likely. Best of The Hollywood Reporter 'The Studio': 30 Famous Faces Who Play (a Version of) Themselves in the Hollywood-Based Series 22 of the Most Shocking Character Deaths in Television History A 'Star Wars' Timeline: All the Movies and TV Shows in the Franchise Solve the daily Crossword
